

## **Royal Stoke University Hospital**

**Quality, Safety and Compliance Department** 

Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Date: 24th May 2019

Ref: FOIA Reference 2019/20-097

Email foi@uhnm.nhs.uk

## Dear

I am writing in response to your email dated 20<sup>th</sup> May 2019 requesting information under the Freedom of Information Act (2000) regarding.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

- Q1 Within your health Trust how many patients are, within the past 6 months that you have data available, being treated with the following treatments? This is regardless for the disease being treated.
  - Disodium pamidronate (Aredia)
  - Ibandronic acid or ibandronate (Bondronat)
  - Sodium clodronate (Bonefos, Clasteon, Loron)
  - Zoledronic acid or zoledronate (Zometa)
  - Denosumab (Xgeva)
  - Omalizumab [Xolair]
  - Mepolizumab [Nucala]
  - Reslizumab [Cingaero]
  - Benralizumab [Fasenra]
- A1 Please see below: note that UHNM pharmacy only holds information on drugs issued to patients, not on drugs used as part of treatments for patients.

Disodium Pamidronate (Aredia):	0
Ibandronic Acid (Bondronat):	0
Sodium Clodronate (Bonefos,	0
Clasteon, or Loron):	
Zoledronic Acid (Zometa):	0
Denosumab (Xgeva):	143
Omalizumab (Xolair):	75
Mepolizumab (Nucala):	<5







## Q2 How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab?

A2 Six paediatric patients have been treated in the last 6 months with Xolair/omalizumab. (Note that UHNM pharmacy only holds information on drugs issued to patients, not on drugs used as part of treatments for patients)

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <a href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</a>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <a href="http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx">http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</a>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,







Lean Cennert.

Jean Lehnert Information Governance Manager



